BL-8040: Ph II started

BioLineRx said the University of Texas MD Anderson Cancer Center began an open-label, U.S. Phase II trial to evaluate subcutaneous 1.25 mg/kg BL-8040 plus 200 mg IV Keytruda pembrolizumab in about 15 patients. Patients will receive once-daily BL-8040 on days 1-5 and 8-12 of the first 21-day cycle and on days 1, 4, 8 and 11 of each subsequent cycle. After the first cycle, patients will receive Keytruda on day 1 of each cycle...